Search Results

1,760 Results for "perlara pbc".

Sort By

Press Releases

PBC Biomed Appoints Mark McMahan as Chief Commercial Officer

October 7, 2025
·
1 min read
Press Releases

Rarity PBC Raises $4.6 Million Seed Financing to Advance Gene Therapy for ADA-SCID

October 30, 2025
·
4 min read
Press Releases

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

November 10, 2025
·
11 min read
Press Releases

Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

November 10, 2025
·
14 min read
Press Releases

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

October 24, 2025
·
17 min read
Press Releases

Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold

September 12, 2025
·
9 min read
Press Releases

Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

May 9, 2025
·
10 min read
Biotech Bay

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced interim results from two Phase 2b studies evaluating volixibat, an oral ileal bile acid transporter (IBAT) inhibitor in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

June 17, 2024
·
9 min read
Press Releases

Preliminary Results from IDE Study on Ringer™ Perfusion Balloon Catheter (PBC) Reported from Podium at CTO Plus Conference

March 28, 2025
·
4 min read
Pharm Country

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

Intercept Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Ocaliva for the treatment of individuals with primary biliary cholangitis (PBC).

February 29, 2024
·
9 min read